Enliven Therapeutics (ELVN) Stock Price, News & Analysis

Company Overview

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications. Enliven applies structure-guided drug design and advanced screening technologies to optimize potency, selectivity and oral bioavailability of its lead compounds. Preclinical studies have demonstrated proof-of-concept in multiple tumor models, supporting planned clinical investigations aimed at overcoming resistance mechanisms that limit the efficacy of conventional therapies.

Headquartered in the greater Boston area, Enliven Therapeutics operates in a hub of biopharmaceutical innovation and maintains strategic collaborations with academic institutions and contract research organizations. The company’s management team brings together seasoned executives and scientists with extensive experience in oncology drug discovery and clinical development. Through its focused R&D strategy, Enliven seeks to advance novel precision therapies that address critical unmet needs in cancer treatment.

Key Stats

• Today's Range: $20.35 to $21.18
• 50-Day Range: $17.69 to $23.34
• 52-Week Range: $13.30 to $30.03
• Volume: 381,743 shs
• Average Volume: 375,265 shs
• Market Capitalization: $1.24 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.20
• Consensus Rating: Buy

Enliven Therapeutics Stock Analysis - MarketRank™

Enliven Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 501st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Enliven Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Enliven Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Enliven Therapeutics are expected to decrease in the coming year, from ($1.95) to ($2.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enliven Therapeutics is -10.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enliven Therapeutics is -10.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enliven Therapeutics has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.95% of the float of Enliven Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Enliven Therapeutics has a short interest ratio ("days to cover") of 9.7.

Change versus previous month

Short interest in Enliven Therapeutics has recently decreased by 2.76%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enliven Therapeutics does not currently pay a dividend.

Dividend Growth

Enliven Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.95% of the float of Enliven Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Enliven Therapeutics has a short interest ratio ("days to cover") of 9.7.

Change versus previous month

Short interest in Enliven Therapeutics has recently decreased by 2.76%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.87

News Sentiment

Enliven Therapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Enliven Therapeutics this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for ELVN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,486,831.00 in company stock.

Percentage Held by Insiders

25.90% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELVN Stock Analysis - Frequently Asked Questions

How have ELVN shares performed this year?

Enliven Therapeutics' stock was trading at $22.50 at the beginning of 2025. Since then, ELVN shares have decreased by 6.9% and is now trading at $20.95.

How were Enliven Therapeutics' earnings last quarter?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) released its earnings results on Wednesday, August, 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04.

Who are Enliven Therapeutics' major shareholders?

Top institutional shareholders of Enliven Therapeutics include Commodore Capital LP (9.56%), Geode Capital Management LLC (1.80%), 5AM Venture Management LLC (1.57%) and TCG Crossover Management LLC (1.01%). Insiders that own company stock include Joseph P Lyssikatos, Samuel Kintz, 5Am Partners Vi, Llc, Anish Patel, Rishi Gupta, Richard A Heyman, Benjamin Hohl and Rahul D Ballal.
View institutional ownership trends.

How do I buy shares of Enliven Therapeutics?

Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enliven Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enliven Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELVN
• CIK: 1672619
• Web: imaratx.com
• Phone: 617-927-9989
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Enliven Therapeutics: $41.20
• High Price Target: $52.00
• Low Price Target: $27.00
• Potential Upside/Downside: +100.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$89.02 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -29.15%
• Return on Assets: -27.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 32.58
• Quick Ratio: 32.58

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.25 per share
• Price / Book: 2.49

Miscellaneous

• Outstanding Shares: 59,240,000
• Free Float: 43,894,000
• Market Cap: $1.22 billion
• Optionable: Optionable
• Beta: 0.89